A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy

Launched by NATIONAL ATOMIC RESEARCH INSTITUTE, TAIWAN · Dec 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging method using a substance called Ga-68 Dolacga to check liver function and see how well tumors respond to a treatment called proton therapy in patients with liver cancer, also known as hepatocellular carcinoma (HCC). The goal is to understand how the liver is doing before and after the treatment, which can help doctors make better decisions for patient care.

To participate in this study, you need to be between 20 and 80 years old, have a diagnosis of hepatocellular carcinoma, and be scheduled for proton therapy. Other important criteria include having a good overall health status and not having severe liver problems. If you join, you will receive the investigational imaging method before and after your proton therapy, and the researchers will monitor your liver function and any side effects. This study is not yet open for participants, but it aims to improve understanding of liver health in people undergoing cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with hepatocellular carcinoma and scheduled to have the PBT.
• • 20\~80 years old
• • Performance status: ECOG 0-1
• • Child-Pugh class A
• Exclusion Criteria:
• • Massive or uncontrolled ascites
• • Concurrent with other malignancy
• • Under pregnancy or breastfeeding
• • With distant metastasis
• • Allergic to investigational drug(s) or similar drug(s)/ formulation(s);
• • Known hypersensitivity to PRIMOVIST
• • Acute or chronic severe renal insufficiency (glomerular filtration rate \<30 mL/min/1.73m\^2)
• • General PET and MRI exclusion criteria
• • Can't follow our follow-up schedule because of any reason